https://www.avient.com/sites/default/files/2021-10/microbial-susceptibility-of-various-polymers-and-evaluation.pdf
Simões, V.
Wozniak, mSphere 2016, 1, e00194-16. [33] V.
https://www.avient.com/sites/default/files/2021-03/avient-antitrust-2021-update-turk-a4.pdf
× Diskutovat s konkurentem, kterým zákazníkům společnost nemá v úmyslu prodávat nebo od kterých dodavatelů společnost nemá v úmyslu nakupovat. × Dohodnout se s konkurenty na rozdělení oblastí, produktů nebo zákazníků. × Dohodnout se s kýmkoli na neobchodování s další stranou, nabádat k tomu nebo to nařizovat. × Diskutovat o konkrétním strategickém plánování nebo marketingových informacích, včetně aktuální kapacity a vytížení, inovací a přestaveb, budoucích produktových nebo tržních plánů nebo jiných citlivých s ohledem na konkurenci.
https://www.avient.com/sites/default/files/2023-08/Avient General Purchase Conditions.pdf
Supplier shall timely provide Avient with (copies of) all applicable licenses, documents, information, specifications and instructions necessary for safe and proper transport, use, Avient Terms and Conditions of Purchase for Goods and/or Services treatment, process and storage of the Goods and with all certificates of analysis/conformity as customarily supplied. 5.3 In addition to all express and implied warranties provided by law or otherwise, Supplier warrants to Avient good and marketable title to the Goods free and clear of all liens and encumbrances and that the Goods shall: (i) conform to all specifications, and other descriptions furnished by Avient, offered by Supplier or agreed and attached hereto, as applicable, and to all samples provided by Supplier; (ii) be new and free from all defects in materials; (iii) be of merchantable quality; (iv) be safe and fit and sufficient for the purposes intended by Avient to the extent known or reasonably knowable by Supplier; (v) conform with all applicable laws in the country of production and delivery (including without limitation EU Chemicals REACH, WEE and RoHS; Occupational Safety and Health Act of 1970, Toxic Substances Control Act, California Health and Safety Code Section 25249.5 et seq.
Termination and suspension 18.1 Avient is entitled to suspend the performance of its obligations in whole or in part or terminate the Agreement with immediate effect, without prejudice to its right to claim damages and without any compensation to or indemnification of Supplier (i) in case Supplier has been declared bankrupt, is in a state of liquidation, has ceased or suspended whole or substantial part of its business, is subject of a court order or preventative legal scheme of settlement (ii) in case of non-compliance with clause 12 including but not limited to, the Avient Supplier Code of Conduct, import, export or chemical control regulations, anti-bribery laws, privacy laws or the provisions of safety, health, environment and security (iii) in case of not approved changes in accordance with clause 10; (iv) failure to make timely progress, nonperformance, or breach by Supplier of the Agreement; and (v) for convenience by written notice to the Supplier in which latter case Avient and Supplier shall negotiate reasonable termination charges limited to Supplier’s direct costs of materials and labor incurred to the date Avient Terms and Conditions of Purchase for Goods and/or Services of termination.
https://www.avient.com/sites/default/files/AVNT February IR Presentation_w_Non-GAAP Recs.pdf
Avient corporation first quarter 2023 results AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) F E B R UA RY 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
https://www.avient.com/sites/default/files/2024-11/AVNT M11 Investor Presentation_w_Non-GAAP.pdf
Microsoft PowerPoint - AVNT M11 Investor Presentation AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) N OV E M B E R 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
https://www.avient.com/sites/default/files/resources/PolyOne%25202012%2520Annual%2520Report.pdf
John V.
Gross v.
Styled Faulkner v.
https://www.avient.com/sites/default/files/2023-11/AVNT November IR Presentation.pdf
AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) N OV E M B E R 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
& Canada 50% EMEA 25% Asia 16% Latin America 9% 2021 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 19% Industrial 16% Building and Construction 10% Telecommunications 4% Energy 2% END MARKET REVENUE (1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs $2,402M $409M $919M $164M $1,631M $94M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $581M$4,819M (1) Transportation 11% Healthcare 15% 24 Packaging 34% Consumer 21% Healthcare 8% Industrial 16% Building & Construction 10% Transportation 9% Energy 1% Telecommunications 1% C O L O R , A D D I T I V E S & I N K S 2021 REVENUE | $2 .4 BILL ION US & Canada 32% EMEA 40% Asia 21% Latin America 7% END MARKET REGION 25 All charts reflect 2021 financials S P E C I A LT Y E N G I N E E R E D M AT E R I A L S Consumer 27% Healthcare 10% Packaging 7% Telecommunications 16% Transportation 11% Industrial 11% Building & Construction 11% Energy 7% 2021 REVENUE | $919 MILLION END MARKET US & Canada 55% EMEA 25% Asia 20% REGION 26 All charts reflect 2021 financials D I S T R I BU T I O N Healthcare 26% Consumer 23% Packaging 5% Industrial 20% Transportation 16% Building and Construction 8% Energy 1% Telecommunications 1% US & Canada 80% Asia 3% Latin America 17% END MARKET REGION K E Y S U P P L I ER S 2021 REVENUE | $1 .6 B ILL ION 27 All charts reflect 2021 financials TOTA L C O M PA N Y R E G I O N A L S A L E S BY END MARKET Packaging 30% Consumer 26%Healthcare 13% Industrial 14% Building & Construction 5% Telecommunications 2% Energy 2% Asia (16% of sales) Transportation 8% Packaging 32% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 12% Telecommunications 5% Energy 4% EMEA (25% of sales) Transportation 12% 28 Consumer 25% Healthcare 19% Packaging 10% Industrial 17% Building & Construction 10% Telecommunications 4% Energy 2% US & Canada (50% of sales) Transportation 13% Packaging 38% Consumer 33% Healthcare 8% Industrial 10% Building & Construction 5% Telecommunications 1% LATAM (9% of sales) Transportation 5% All charts reflect 2021 financials Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/resources/PolyOne%25202017%2520Proxy%2520Statement.PDF
Richardson(1) 45,000 29,712 51,812 V.
Richardson 17,225 29,815 - 11,862 V.
Richardson N/A - - - V.
https://www.avient.com/sites/default/files/2021-01/avient-colorants-belgium-registered-publication.pdf
TITRE V.